HIV-1 protease is a widely exploited target for the development
of antiviral agents against HIV-1 and several potent protease
inhibitors are widely used in highly active antiretroviral
therapy.1 However, when full viral inhibition is not achieved,
new drug-resistant variants emerge with the accumulation of
mutations in the protease coding region, causing treatment